Anthropic CEO says AI’s biotech breakthrough may still be a decade away despite current hype

In a recent on‑stage conversation, Matthew Herper interviewed Dario Amodei, the CEO and co‑founder of Anthropic, about the role of artificial intelligence in biotechnology. The discussion took place at an Anthropic event where the company highlighted its focus on public‑benefit initiatives.

Amodei recalled a 2024 essay in which he envisioned large language models, such as Anthropic’s Claude, enabling a decade’s worth of scientific progress each year – effectively compressing a century of discovery into ten years. He described that vision as a powerful motivator for pharma companies to explore AI tools now.

However, he cautioned that the promised acceleration is not yet realistic. He cited three main hurdles: the current models are not as capable as future versions, researchers need time to learn how to apply the tools effectively, and the supporting infrastructure and regulatory frameworks will evolve slowly.

Despite these limitations, Amodei noted that pharmaceutical firms are already investing in AI because the technology shows genuine potential, even if the transformative impact may take years to materialize.